Protalix BioTherapeutics, Inc. (PLX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 25M 50M 75M FY09: 388K FY10: 6.6M FY11: 8.4M FY12: 34.9M FY13: 0 FY14: 3.5M FY15: 4.4M FY16: 9.2M FY17: 21.1M FY18: 34.2M FY19: 54.7M FY20: 62.9M FY21: 38.4M FY22: 47.6M FY23: 65.5M FY24: 53.4M FY25: 52.7M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

-9M 0 9M 18M 27M FY09: -3.2M FY10: 6.9M FY11: 1.4M FY12: 26.3M FY13: 0 FY14: 2.9M FY15: 3.6M FY16: 801K FY17: 4M FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M FY09: -32M FY10: -30M FY11: -36.5M FY12: -12.2M FY13: -34.1M FY14: -28.6M FY15: -23.7M FY16: -33.2M FY17: -34.5M FY18: -19.3M FY19: -10.7M FY20: 2.7M FY21: -20.5M FY22: -13M FY23: 10.5M FY24: 3.9M FY25: -5.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-90M -60M -30M 0 30M 60M 90M FY09: -31.4M FY10: -29M FY11: -36.5M FY12: -11.6M FY13: -27.8M FY14: -29.9M FY15: 58M FY16: -29.4M FY17: -83.4M FY18: -26.5M FY19: -18.3M FY20: -6.5M FY21: -27.6M FY22: -14.9M FY23: 8.3M FY24: 2.9M FY25: -6.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 10M 20M 30M FY09: 3.6M FY10: 4.4M FY11: 1.5M FY12: 8.1M FY13: 0 FY14: 630K FY15: 730K FY16: 8.4M FY17: 15.2M FY18: 9.3M FY19: 10.9M FY20: 10.9M FY21: 16.3M FY22: 19.6M FY23: 23M FY24: 24.3M FY25: 27M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-40M -20M 0 20M 40M 60M FY09: 44.5M FY10: -38.5M FY11: -23.6M FY12: 635K FY13: -30.7M FY14: -29.3M FY15: -24.3M FY16: -32.1M FY17: -10M FY18: -7.7M FY19: -19.4M FY20: -26.1M FY21: -10.3M FY22: -25M FY23: -1.3M FY24: 8.7M FY25: -12M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY09: 38.3M FY10: -46.3M FY11: -29.3M FY12: -1.4M FY13: -32.5M FY14: -30.1M FY15: -24.7M FY16: -32.9M FY17: -11M FY18: -8.4M FY19: -20M FY20: -26.8M FY21: -11.7M FY22: -25.6M FY23: -2.5M FY24: 7.4M FY25: -13.6M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY19: 14.8M FY20: 29.1M FY21: 44.1M FY22: 48.5M FY23: 82.4M FY24: 81.1M FY25: 78.5M FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '10: -0.36 Q1 '11: -0.40 Q2 '11: -0.68 Q3 '11: -0.81 Q4 '11: -0.60 Q1 '12: -0.59 Q2 '12: -0.33 Q3 '12: -0.17 Q4 '12: 0.08 Q1 '13: 0.06 Q2 '13: -0.11 Q3 '13: -0.23 Q4 '13: -0.20 Q1 '14: -0.17 Q2 '14: -0.17 Q3 '14: -0.20 Q4 '14: -0.17 Q1 '15: -0.31 Q2 '15: -0.29 Q3 '15: -0.24 Q4 '15: 0.62 Q1 '16: 0.59 Q2 '16: 0.53 Q3 '16: 0.50 Q4 '16: -0.29 Q1 '17: -0.68 Q2 '18: -6.02 Q3 '18: -5.97 Q4 '18: -0.55 Q1 '19: -1.00 Q2 '19: -1.46 Q3 '19: -1.66 Q4 '19: -1.24 Q1 '20: -0.64 Q2 '20: -0.25 Q3 '20: -0.15 Q4 '20: -0.22 Q1 '21: -0.46 Q2 '21: -0.58 Q3 '21: -0.53 Q4 '21: -0.62 Q1 '22: -0.53 Q2 '22: -0.39 Q3 '22: -0.37 Q4 '22: -0.30 Q1 '23: -0.30 Q2 '23: 0.02 Q3 '23: 0.05 Q4 '23: 0.09 Q1 '24: 0.08 Q2 '24: -0.16 Q3 '24: -0.09 Q4 '24: 0.04 Q1 '25: 0.05 Q2 '25: 0.08 Q3 '25: 0.08 Q4 '25: -0.09 Q1 '26: 0.18 Q2 '26: 0.23 Q2 '11 Q2 '13 Q2 '15 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.